drugset / Trial / NCT04238624
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is being done to see if adding the study drug, cemiplimab, to the standard therapy with dabrafenib and trametinib is an effective treatment against anaplastic thyroid cancer.
Timeline
- Start
- 2020-01-20
- Primary completion
- 2027-06-20
- Completion
- 2027-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Dabrafenib | Small molecule | 150 mg | Oral |
| Background | Trametinib | Small molecule | 2 mg | Oral |